BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28665480)

  • 41. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis.
    Opelz G; Daniel V; Naujokat C; Fickenscher H; Döhler B
    Lancet Oncol; 2007 Mar; 8(3):212-8. PubMed ID: 17329191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation.
    Li L; Chaudhuri A; Weintraub LA; Hsieh F; Shah S; Alexander S; Salvatierra O; Sarwal MM
    Pediatr Transplant; 2007 Mar; 11(2):187-95. PubMed ID: 17300499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytomegalovirus infection in simultaneous pancreas-kidney transplantation.
    Malaise J; Ricart MJ; Moreno A; Crespo M; Fernández-Cruz L; Van Ophem D; Squifflet JP;
    Transplant Proc; 2005; 37(6):2848-50. PubMed ID: 16182830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The risk of cytomegalovirus recurrence after kidney transplantation.
    Helanterä I; Lautenschlager I; Koskinen P
    Transpl Int; 2011 Dec; 24(12):1170-8. PubMed ID: 21902725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation.
    Le Page AK; Mackie FE; McTaggart SJ; Kennedy SE
    Nephrology (Carlton); 2013 Dec; 18(12):813-9. PubMed ID: 23927085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytomegalovirus infection in a seroendemic renal transplant population: a longitudinal study of virological markers.
    Rao M; Finny GJ; Abraham P; Juneja R; Thomas PP; Jacob CK; Sridharan G
    Nephron; 2000 Apr; 84(4):367-73. PubMed ID: 10754415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
    Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
    Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CMV, EBV, JCV and BKV infection and outcome following kidney transplantation in children initiated on a corticosteroid-minimisation immunosuppressive regimen.
    McCaffrey J; Bhute VJ; Shenoy M
    Pediatr Nephrol; 2021 Oct; 36(10):3229-3240. PubMed ID: 33825043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome.
    Watcharananan SP; Louhapanswat S; Chantratita W; Jirasiritham S; Sumethkul V
    Transplant Proc; 2012 Apr; 44(3):701-5. PubMed ID: 22483472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
    Andreani M; Albano L; Benzaken S; Cassuto E; Jeribi A; Caramella A; Giordanengo V; Bernard G; Esnault V; Seitz-Polski B
    Transplant Proc; 2020; 52(1):204-211. PubMed ID: 31889538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
    Opelz G; Daniel V; Naujokat C; Döhler B
    Transplantation; 2009 Oct; 88(8):962-7. PubMed ID: 19855238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
    Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
    Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?
    Saghafi H; Qorashi M; Heidari A
    Transplant Proc; 2009 Sep; 41(7):2761-3. PubMed ID: 19765428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
    Cameron BM; Kennedy SE; Rawlinson WD; Mackie FE
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27704725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polyoma virus-associated nephropathy and concurrent cytomegalovirus infection in the kidney transplant recipients.
    Park SB; Kwak JH; Lee KT; Hwang EA; Han SY; Kim HT; Cho WH; Choi MS; Kim HC
    Transplant Proc; 2006 Sep; 38(7):2059-61. PubMed ID: 16979999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort.
    Pullerits K; Garland S; Rengarajan S; Guiver M; Chinnadurai R; Middleton RJ; Chukwu CA; Kalra PA
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
    Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
    Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
    López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM
    Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.